The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A. Bjarnason, Naveen S. Basappa, Sebastién J. Hotte et al.|European Journal of Cancer|2019Cited by 28
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.Georg A. Bjarnason, Naveen S. Basappa, Jennifer J. Knox et al.|Journal of Clinical Oncology|2017Cited by 7
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.Georg A. Bjarnason, J. A. Miller, Naveen S. Basappa et al.|Journal of Clinical Oncology|2013Cited by 5
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).Georg A. Bjarnason, Naveen S. Basappa, Jennifer J. Knox et al.|Journal of Clinical Oncology|2015Cited by 5